A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1255-1263

  Adelglass, Jeffrey ^a   Jones, Terry M ^a   Ruoff, Gary ^a   Kahn, James B ^a   Wiesinger, Barbara A ^a   Rielly Gauvin, Katie ^a   Siu, Cynthia O ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; LEVOFLOXACIN;

ADULT; ANTIBACTERIAL ACTIVITY; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; LEGIONELLA PNEUMOPHILA; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SINGLE BLIND PROCEDURE; SINUSITIS; STATISTICAL ANALYSIS; STREPTOCOCCUS PNEUMONIA; TASTE DISORDER;

ABDOMINAL PAIN; ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CLARITHROMYCIN; DIARRHEA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NAUSEA; OFLOXACIN; QUALITY OF LIFE; RECURRENCE; SINGLE-BLIND METHOD; SINUSITIS; TASTE DISORDERS; TREATMENT OUTCOME;

EID: 0031726001     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. U.S. Department of Health and Human Services. National health survey. Prevalence of selected chronic conditions, United States, 1983-85. Hyattsville, MD: U.S. Department of Health and Human Services, 1987.
2. Schwartz R. The diagnosis and management of sinusitis. Nurse Pract 1994;19:58-63.
3. Diaz I, Bamberger DM. Acute sinusitis. Semin Respir Infect 1995;10:14-20.
4. Kennedy DW. First-line management of sinusitis: a national problem? Otolaryngol Head Neck Surg 1990;103:884-6.
5. Levine HI. Acute sinusitis: impact and management. Cleve Clin J Med 1991;58:296-7.
6. U.S. Department of Health and Human Services. National health survey. Prevalence of selected chronic conditions, United States, 1979-81. Hyattsville, MD: U.S. Department of Health and Human Services, 1986.
7. Loury M, Kennedy D. Chronic sinusitis and nasal polyposis. In: Getchell T, Doty R, Bartoshuk L, eds. Smell and taste in health and disease. New York: Raven Press, 1991:517-28.
8. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995;273:214-19.
9. Willett LR, Carson JL, Williams JW. Current diagnosis and management of sinusitis. J Gen Intern Med 1994;9:38-45.
10. Ferguson BJ. Acute and chronic sinusitis. How to ease symptoms and locate the cause. Postgrad Med 1995;97:45-57.
11. Van Duijn NP, Brouwer HJ, Lamberts H. Use of symptoms and signs to diagnose maxillary sinusitis in general practice: comparison with ultrasonography. BMJ 1992;305:684-7.
12. Gwaltney JM Jr, Sydnor A Jr, Sande MA. Etiology and antimicrobial treatment of acute sinusitis. Ann Otol Rhinol Laryngol 1981;90(suppl 84):68-71.
13. Gwaltney JM Jr, Scheld WM, Sande MA, Sydnor A. The microbial etiology and anti-microbial therapy of adults with acute community-acquired sinusitis: a fifteen-year experience at the University of Virginia and review of other selected studies. J Allergy Clin Immunol 1992;90:457-62.
14. Douville L. Management of acute sinusitis. J Am Acad Nurse Pract 1995;7:407-11.
15. Stafford CT. The clinician's view of sinusitis. Orolaryngol Head Neck Surg 1990;103:870-4.
16. Giebink GS. Childhood sinusitis: pathophysiology, diagnosis and treatment. Pediatr Infect Dis J 1994;13(suppl):S55-8.
17. Baroody FM. Medical treatment of sinusitis. Lab Med J 1994;42:190-5.
18. Isaacson G. Sinusitis in childhood. Pediatr Otolaryngol 1996;43:1297-1318.
19. Zeckel ML, Johns D, Masica DN, Farlow D. Twice-daily dosing of loracarbef 200 mg versus 400 mg in the treatment of patients with acute maxillary sinusitis. Clin Ther 1995;17: 214-30.
20. Marchi E. Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis. Curr Med Res Opin 1990;12: 19-24.
21. Karma P, Pukander J, Penttila M, et al. The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis. J Antimicrob Chemother 1991;27(suppl A):83-90.
22. Casiano RR. Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Am J Med 1991;91(suppl 3A):27S-30.
23. Felstead SJ, Daniel R, and the European Azithromycin Study Group. Short-course treatment of sinusitis and other upper respiratory tract infections with azithromycin: a comparison of erythromycin and amoxicillin. J Int Med Res 1991;19:363-72.
24. Amin NM, Breadon G. An open-label, noncomparative study to evaluate the efficacy, safety, and tolerability of azithromycin in the treatment of patients with acute sinusitis. Clin Ther 1995;17:701-7.
25. Dubois J, Saint-Pierre C, Tremblay C. Efficacy of clarithromycin v. amoxicillin/clavulanate in the treatment of acute maxillary sinusitis. Ear Nose Throat J 1993;72:804-10.
26. Sydnor TA, Koop EJ, Anthony KE, et al. An open-label assessment of the activity of levofloxacin for the treatment of acute community-acquired bacterial sinusitis in adults. Ann Allergy Asthma Immunol 1998;80:357-62.
27. Adelglass J, DeAbate CA, McElvaine P, et al. A comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute bacterial sinusitis in adults. Clin Infect Dis 1996;23:913.
28. Data on file. Hoechst Marion-Roussel, Bridgewater, NJ.
29. Isaacson DM, Fernandez JA, Frosco M, et al. Levofloxacin: a review of its antibacterial activity. Recent Res Dev Antimicrob Agents Chemother 1996;1:391-439.
30. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994;47:677-700.
31. Une T, Fujimoto T, Sato K, Osada Y. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother 1988;32:1336-40.
32. Neu H, Chin N-X. In vitro activity of S-ofloxacin. Antimicrob Agents Chemother 1989;33:1105-7.
33. Klugman KP, Capper T. Levofloxacin in vitro activity and synergistic activity in combination with other antibacterials against antibiotic-resistant S. pneumoniae, and selection of resistant mutants. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
34. Markus A, Isert D, Kiesel N, Seibert G. Killing activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in vitro and in vivo. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-20, 1995.
35. Plouffe JF, and the Franklin County Pneumonia Study Group. Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1996;25:43-5.
36. Biedenbach DJ, Jones RN. The comparative antimicrobial activity of levofloxacin tested against 350 clinical isolates of streptococci. Diagn Microbiol Infect Dis 1996;25:47-51.
37. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32:101-19.
38. Baba S, Miyamoto N, Nanai O, et al. Study on the penetration of levofloxacin (DR-3355) into the otorhinolaryngeal tissues and discharges in patients. Chemotherapy 1992;40(suppl 3):326-33.
39. Chow AT, Wong FA, Rogge MC, Flor SC. Pharmacokinetics of levofloxacin after 500 mg b.i.d. and 500 mg q.d. oral doses in two different groups of healthy volunteers. In: Abstracts of the 4th international symposium on new quinolones, Munich, Germany, August 27-29, 1992.
40. File TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of IV/PO levofloxacin vs ceftriaxone/cefuroxime axetil in the treatment of adults with community-acquired pneumonia. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 15-18, 1996.
41. DeAbate CA, Russell M, McElvaine P, et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 1997;42: 206-13.
42. Habib MP, Gentry LO, Rodriguez-Gomez G, et al. A multicenter, randomized study comparing the efficacy and safety of oral levofloxacin vs cefaclor in the treatment of acute bacterial exacerbations of chronic bronchitis. Presented at the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 15-18, 1996.
43. Data on file. Ortho-McNeil Pharmaceutical, Raritan, NJ.
44. Division of Anti-Infective Products. Clinical development and labeling of anti-infective drug products. 2. Points regarding clinical trial design/conduct. IV. Issues regarding adequacy of trials. Washington, DC: Food and Drug Administration, October 1992.
45. Gwaltney JM Jr. Acute community-acquired sinusitis. Clin Infect Dis 1996;23:1209-25.
46. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77-83.
47. Breiman RF, Butler JC, Tenover FC, et al. Emergence of drug-resistant pneumococcal infections in the United States. JAMA 1994;271:1831-5.
48. Kennedy DW. Medical management of sinusitis: educational goals and management guidelines. Ann Otol Rhinol Laryngol 1995;104:22-31.
49. Brook I. Microbiology and management of sinusitis. J Otolaryngol 1996;25:249-56.
50. Thornbserry C, Ogilvie P, Kahn J, et al. Surveillance of antimicrobial resistance in S. pneumoniae, H. influenzae, and M. catarrhalis in the U.S. during the 1996-1997 respiratory season. Diagn Microbiol Infect Dis 1997;29:249-57.